Get to know our clinical trials

Trial of brensocatib administered once daily for 52 weeks in subjects with bronchiectasis without cystic fibrosis.

THE PURPOSE OF THIS STUDY IS TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF BRENSOCATIB AS A TREATMENT FOR BRONCHIECTASIS NOT ASSOCIATED WITH CYSTIC FIBROSIS.

Status
reclutamiento
headquarters
Pamplona

Technical Summary

  • INSMED INCORPORATED / PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF BRENSOCATIB ADMINISTERED ONCE DAILY FOR 52 WEEKS IN SUBJECTS WITH BRONCHIECTASIS WITHOUT CYSTIC FIBROSIS: THE ASPEN STUDY.
  • Code EudraCT: 2020-003688-25
  • Protocol number: INS1007-301
  • Promoter: Insmed Incorporated
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.